Why BeOne Medicines (ONC) Is Up 9.2% After EU Nod for TEVIMBRA in Rare Cancer and What's Next

• In July 2025, BeOne Medicines Ltd. announced European Commission approval for TEVIMBRA® (tislelizumab) plus chemotherapy for first-line treatment of metastatic or recurrent nasopharyngeal carcinoma in adults, based on positive results from a global Phase 3 trial.
• This decision marks a significant advance for patients with a rare cancer and highlights TEVIMBRA’s expanding international clinical and regulatory footprint.
• We’ll examine how this regulatory milestone strengthens BeiGene’s investment narrative, particularly through its expanding oncology market presence in Europe.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

BeOne Medicines Investment Narrative Recap

Owning BeOne Medicines means believing in their ability to build a global oncology business, powered by product approvals like TEVIMBRA® in rare cancers. The recent European Commission approval strengthens near-term confidence in clinical and commercial execution, yet does not materially resolve the ongoing risks associated with aggressive international expansion, particularly cost and operational complexity in new markets.

Among recent company announcements, the June 25th CHMP positive opinion on expanding BRUKINSA® tablet formulation across approved indications stands out, underscoring BeOne’s intent to broaden its European footprint. Both developments signal progress on geographic growth catalysts, but also underscore the significant execution risk inherent in scaling operations across diverse regulatory environments.

However, investors should be aware that despite this momentum, regulatory and cost hurdles in complex new markets remain a...

Read the full narrative on BeOne Medicines (it's free!)

BeOne Medicines' narrative projects $7.2 billion in revenue and $1.2 billion in earnings by 2028. This requires 23.4% yearly revenue growth and a $1.84 billion increase in earnings from the current level of -$644.8 million.

Uncover how BeOne Medicines' forecasts yield a $360.46 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Fair value estimates from the Simply Wall St Community range widely, from US$255.78 to US$605.07 across 3 perspectives. While this approval addresses the company’s growth ambitions in Europe, new market complexity can directly impact cost controls and future earnings, so it pays to explore how different investors see the risk-reward balance.

Explore 3 other fair value estimates on BeOne Medicines - why the stock might be worth 8% less than the current price!

Build Your Own BeOne Medicines Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your BeOne Medicines research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free BeOne Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BeOne Medicines' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com